YAFO Acts as Exclusive Financial Advisor for Tarveda Therapeutics in its Licensing-out Transaction with SciClone
Tarveda Therapeutics, Inc. (“Tarveda”), a clinical stage biopharmaceutical company developing a new class of potent and selective precision oncology medicines, which it refers to as Pentarin® miniature drug conjugates, for the treatment of patients with various solid tumor malignancies, and SciClone Pharmaceuticals International Ltd.,
YAFO Acts as Exclusive Financial Advisor for Tarveda Therapeutics in its Licensing-out Transaction with SciClone
雅法担任 Tarveda Therapeutics独家顾问，完成与赛生制药商业许可交易
Transaction Overview 交易概览
Tarveda Therapeutics, Inc. (“Tarveda”), a clinical stage biopharmaceutical company developing a new class of potent and selective precision oncology medicines, which it refers to as Pentarin® miniature drug conjugates, for the treatment of patients with various solid tumor malignancies, and SciClone Pharmaceuticals International Ltd., (“SciClone”) today announced that they have entered into a licensing agreement for PEN-866, the initial clinical program from Tarveda’s HSP90 binding miniature drug conjugate platform, which is designed to bind to the activated form of Heat Shock Protein 90 (HSP90) to accumulate and release its potent topoisomerase 1 inhibitor (SN-38) payload in solid tumors.
Under the terms of the agreement, SciClone will obtain exclusive licensing rights to co-develop and commercialize PEN-866 in the Greater China territory, including mainland China, Hong Kong, Macau and Taiwan. SciClone will be responsible for development, product registration and commercialization in these territories. Per the agreement, SciClone will pay Tarveda an upfront payment of U.S. $4 million with the right to make a future equity investment in Tarveda of up to U.S. $5 million. Tarveda will be eligible to receive up to $75 million in aggregate development, approval and commercial sales milestone payments. Tarveda is also eligible to receive royalties based on sales in the Greater China territory. Shanghai YAFO Capital (YAFO Life Science) acted as banking and financial advisor on this transaction for Tarveda.
Tarveda Press Release: https://www.businesswire.com/news/home/20200319005765/en/
PEN-866是一种微型药物偶联物，可优先结合实体瘤中HSP90的活化形式，并与拓扑异构酶1抑制剂（SN-38）（一种有效的抗癌有效载荷）相连。PEN-866被设计为在肿瘤中积累并保留在肿瘤中。随着SN-38有效载荷随着时间的流逝在肿瘤中裂解，SN-38在肿瘤中的持续释放导致DNA损伤延长和肿瘤消退，如在多个患者来源的和其他异种移植肿瘤模型中所证明的。PEN-866最近已完成其1/2a期临床试验的1期，所有患者的剂量递增和安全性试验。PEN-866是Tarveda的HSP90结合药物平台上的第一个微型药物结合物。
About Tarveda
Tarveda Therapeutics is a clinical stage biopharmaceutical company developing a new class of potent and selective precision oncology medicines, which it refers to as Pentarin® miniature drug conjugates, for the treatment of patients with various solid tumor malignancies. Tarveda’s Pentarin miniature drug conjugates are designed to take the best properties of both small molecule drugs and antibody drug conjugates to form a miniature drug conjugate able to penetrate into solid tumors, selectively bind to the desired tumor targets and accumulate the anti-cancer payloads directly in tumor cells. The anti-cancer payload is retained in tumor and then released over time causing the anti-cancer payload to become active in the tumor.
Tarveda Therapeutics是一家临床阶段的生物制药公司，专注于研发肿瘤领域的创新治疗药物。 公司的核心产品是两款临床阶段肿瘤治疗适应症的小分子药物偶联物（SMDC）研发平台。公司研 发的小分子药物偶联物（ 小分子配体 < 2KD ）能够快速有效的渗透肿瘤内部，并延长细胞毒药物（payload）发挥作用的时间。公司的股东包括世界知名医疗基金Versant Ventures, NEA, Novo A/S, NanoDimension等，融资总额超过1亿美金。
About SciClone 赛生医药
SciClone Pharmaceuticals is a private-owned specialty pharmaceutical company with a substantial commercial business in Greater China and a product portfolio focusing oncology and infectious diseases. SciClone is dedicated to improving patients’ health by providing top-tier healthcare products and services with global standards of care. SciClone's proprietary lead product, ZADAXIN® (Thymalfasin), is approved in over 30 countries and may be used for the treatment of certain cancers, hepatitis, and as a vaccine adjuvant, according to the local regulatory approvals. In addition, SciClone currently market a number of oncology products as commercial partner for Baxter, Pfizer and Boston Scientific in China. The Company also have a robust product pipeline aiming to address the unmet needs in severe and specialized disease areas, especially oncology.
赛生医药是一家私有专业制药公司，专注于研发和商业化肿瘤学和感染性疾病领域的高质量药品，在大中华区拥有大量业务。赛生医药致力于通过提供具有国际水平的医疗产品和服务来提高患者的健康。赛生药业的核心产品ZADAXIN(日达仙)，在超过30多个国家获得批准，可用于治疗肝炎，某些类型的癌症和作为疫苗佐剂使用。 此外，赛生药业通过与Baxter、辉瑞和波士顿科学等机构合作，将其肿瘤产品在中国商业化并推向市场。该公司还具有强大的产品管线，旨在解决严重和特殊疾病领域，特别是在肿瘤学领域未被满足的需求。
About YAFO Life Science 雅法全球医疗
YAFO Life Science (YLS) is the healthcare division of YAFO Capital, which is focused on helping leading U.S. and European biopharma and medtech companies to successfully enter the Asian market, especially in China and Japan. YLS also helps domestic pharma companies in global market research, targeting, and negotiation. Along with our local partners, YLS is dedicated to bridging the gap between global medical technologies and the Asian market. For more information regarding YAFO, go to: www.yafocapital.com
雅法全球医疗（YAFO Life Science）是雅法资本旗下的医疗大健康部门，专注于帮助具有“中国角度”的海外医药、医疗器械企业在中国的融资、授权和战略合作；为中国医疗企业提供产品全球授权、海外市场研究服务，寻找海外投资并购标的，及产品商业合作。雅法全球医疗核心合伙人团队均为华尔街资深投行人士或具有跨国药企工作经验；雅法庞大的海外的区域合伙人团队，均具20+年医药行业及交易经验，覆盖美国、日本 、欧洲等主要全球医药创新区域。项目合作请联系：黎琦 | BD Director | 13621979227 | qli@yafocapital.com
For more information please contact:
Fan Zheng 郑帆
Managing Director
fzheng@yafocapital.com
Qi Li 黎琦
BD Director
qli@yafocapital.com
Kun Tao, CFA
Partner, Head of U.S. Business
ktao@yafocapital.com
